Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and cemdisiran long-term extension in paroxysmal nocturnal hemoglobinuria
2021-004931-10Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent serious adverse events. Started Nov 2022; status: active.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2021-004931-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004931-10.